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practice in central Massachusetts were used to identify 1777 patients age q65 years 
as of January 1, 2006 with continuous medical and pharmacy coverage in 2005 
(baseline) and 2006 (study period) and q1 depression diagnosis in 2005. Patients with 
q1 antidepressant claim in 2006 were classiﬁ ed as “treated” and those without an 
antidepressant as “untreated.” Depressed patients were randomly matched to controls 
without depression on age and gender. Baseline comorbidity proﬁ les were compared 
using Chi-square tests. Wilcoxon rank-sum tests and generalized linear models were
used to compare study period direct (medical and pharmacy) costs deﬁ ned as third 
party payments to providers. Depression-related costs were identiﬁ ed using claims
with depression diagnosis and antidepressant prescriptions. RESULTS: A total of 1334 
(75.1%) of depressed patients were treated with antidepressants during the study
period and 443 patients (24.9%) were not treated. Depressed patients were on average 
77 years old and 74.8% were women. Depressed patients had higher rates of mental 
health and physical comorbidities than controls. Treated depressed patients had higher 
rates of mental health comorbidities than the untreated but few differences in rates of 
physical comorbidities. During the study period average annual direct costs were
$14,362 among treated depressed patients, $8,928 among the untreated, and $6,961 
among controls (P  0.01 for all comparisons). Risk-adjusted direct costs were
signiﬁ cantly different between the treated and untreated depressed. Average depres-
sion-related costs were $1,582 among the treated and $133 among the untreated (P
 0.01). CONCLUSIONS: Older depressed patients (both treated and untreated) had
more comorbidities and higher costs compared to controls. Costs and rates of mental
health comorbidities were higher among the treated depressed compared with the
untreated.
PMH30
HOSPITALIZATION COSTS FOR SCHIZOPHRENIA RELAPSES IN A
PUBLIC PSYCHIATRIC INSTITUTION
Verduzco W1, Escobedo O2, Anaya P3
1Mexican Social Security Institute, Mexico City, Mexico, 2Mexican Social Security Institute, 
Mexico City, D.F, Mexico, 3AstraZeneca, Naucalpan, Edo. de Méx, Mexico
OBJECTIVES: To estimate hospitalization costs as well as resources used by schizo-
phrenic patients during a relapse in a public psychiatric hospital. METHODS: A 
documental retrospective analysis of schizophrenia patients with a relapse as the 
principal diagnosis was carried out in a public psychiatric hospital in Mexico. The
range of patients’ age was from 18 to 64 years. Data was collected by a General Physi-
cian through a Case Report Form designed speciﬁ cally for this study. Resources used 
during relapse hospitalization were accrued and ﬁ nal costs were calculated using
unitary costs of the Mexican Social Security Institute (IMSS) for laboratory studies,
physician’s visit, emergency admittance and bed day. Drug costs were obtained from 
public bids of the same institution. Results are presented using descriptive statistics. 
Costs are in US dollars using and exchange rate of 13.5 MXN pesos for 1 US dollar. 
RESULTS: Sample size was of 73 patients with an average follow up of 3.3 years. 
Hospital average length of stay was 20.65 days (4–108), average time between relapses
was 14.66 months (6.47–25.73). The average cost per day was $346 (95% IC,
$331–$360), 96% of this cost represents the average bed day cost reported by the
IMSS. The average cost per relapse was $7,086 ($1,498–$36,288). Alcoholism and 
hypertension were the main comorbidities reported in 10.8% of admitted patients. 
Lack of compliance was the reason for relapse in 95% of the cases. CONCLUSIONS:
Bed day cost is the main component of total costs, therefore it would make sense to 
use those antipsychotic drugs that help reduce the hospital length of stay. The lack of 
compliance is responsible for the vast majority of relapses (95%). A health care 
program focus in increasing drug compliance could decrease institutional general costs
by reducing hospitalizations due to relapses.
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OBJECTIVES: Efﬁ cacy in bipolar disorder (BPD) has been demonstrated for various
atypical antipsychotics (APs). Treatment choice is based on factors including patient
history and clinician preference. Because cost of patient care is often a factor, this
study explored the association between AP treatment choice and subsequent medical 
care costs. METHODS: Patients with BPD and AP treatment were identiﬁ ed in the
2004–2005 PharMetrics Patient-Centric Database. Patients were stratiﬁ ed by the 
most-recently prescribed AP and retained with q12 months continuous enrollment 
before and after their earliest AP claim. Total medical care costs were tallied from all
paid claims for 12 months post AP initiation. Multivariable analyses controlled for 
differences between cohorts. RESULTS: AP patient cohorts were ziprasidone (n  825), 
olanzapine (n  2526), risperidone (n  2309), quetiapine (n  2860) and aripiprazole
(n  1187). Mean age was 39–42 years. Ziprasidone patients were more likely to be 
female. Approximately 25% of the sample had comorbid anxiety and 10% had 
alcohol abuse. The majority had concomitant medication use. After controlling for 
covariates, the ziprasidone group’s 12-month post-initiation total costs ($14,445) were
similar to risperidone ($13,358, p  .06) and olanzapine ($13,780, p  0.24), and,
lower than quetiapine ($15,740, p  0.03) and aripiprazole ($16,360, p  0.01). Older 
age, female gender, pre-index psychiatric admission, comorbidities, and concomitant 
medication were signiﬁ cantly associated with increased costs. Nevertheless, unadjusted
results were similar to multivariable ﬁ ndings. CONCLUSIONS: Twelve months fol-
lowing treatment initiation for BPD, total medical care costs for patients on ziprasi-
done were comparable to those for patients on olanzapine or risperidone, and, 
signiﬁ cantly lower than costs for patients on quetiapine or aripiprazole. If cost is a
factor in AP treatment choice, the ﬁ ndings suggest ziprasidone compares favorably.
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OBJECTIVES: Efﬁ cacy in treating schizophrenia has been demonstrated for a variety 
of atypical antipsychotics (APs). Clinicians will select an appropriate AP based on a
variety of clinical considerations but cost of patient care is increasingly becoming a 
consideration. This study explored the association between AP treatment choice and 
subsequent medical care costs. METHODS: Patients with schizophrenia and AP treat-
ment were identiﬁ ed in the 2004–2005 PharMetrics Patient-Centric Database. Patients
were stratiﬁ ed by the most-recently prescribed AP and retained with q12 months 
continuous enrollment before and after their earliest AP claim. Total and psychiatric-
related medical care costs were tallied from all paid claims for 12 months post AP 
initiation. Multivariable analyses controlled for differences between cohorts.
RESULTS: Patient cohorts were ziprasidone (n  207), olanzapine (n  755), risperi-
done (n  1004), quetiapine (n  404) and aripiprazole (n  367). Mean age was 40–44 
years. Mood disorders, anxiety, alcohol abuse and substance abuse were prevalent 
among the sample. Most patients had concomitant medication use. After controlling 
for covariates, the ziprasidone group’s 12-month post-initiation total costs ($12,920) 
were similar to risperidone ($11,522, p  0.14), olanzapine ($13,398, p  0.65), que-
tiapine ($14,076, p  0.32) and aripiprazole ($13,286, p  0.75). Psychiatric-related
costs accounted for roughly half of total costs and were comparable across cohorts.
Comorbidities and concomitant medication were signiﬁ cantly associated with 
increased costs. Nevertheless, unadjusted results were similar to multivariable ﬁ ndings. 
CONCLUSIONS: In the 12 months following AP initiation total medical care and 
psychiatric-related costs for schizophrenia patients on ziprasidone were comparable 
to those for patients on other APs. If cost is a factor in AP treatment choice, the ﬁ nd-
ings suggest ziprasidone compares favorably.
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OBJECTIVES: Dose escalation of antidepressant therapy is a common but potentially
costly strategy of managing treatment-refractory depression. This study assessed the
cost implications of dose escalation for major depressive disorder (MDD) patients
treated with escitalopram versus venlafaxine extended-release (XR). METHODS:
MDD patients (age q18) who started escitalopram or venlafaxine XR were identiﬁ ed
in the Ingenix Impact Database (2003–2006). The index date was the date when 
patients ﬁ rst received either drug at the label-recommended initial dose (escitalopram:
10 mg/day; venlafaxine XR: 75 mg/day) or high dose (escitalopram: 20 mg/day;
venlafaxine XR: 150 mg/day). Dose escalation was deﬁ ned as having a reﬁ ll with 
daily dose at least double the starting dose during the 6-month post-index period. A 
generalized linear model (GLM) assessed the effects of dose escalation and starting 
dose (recommended vs. high) on total health care costs during the post-index period, 
adjusting for index drug, demographics, comorbidities, and health care utilization at 
baseline. A similar GLM compared total costs between treatment groups, incorporat-
ing the effects of dose escalation and starting dose. RESULTS: 17,638 patients started
on escitalopram (18.6% on high-dose) and 9,252 on venlafaxine XR (46.0% on 
high-dose). Baseline mental comorbidities were similar between treatment groups. 
Venlafaxine XR patients had a 28.5% and 102.0% higher risk of dose escalation
compared to escitalopram patients in the recommended-dose and high-dose sub-
groups, respectively (both P  0.0001). Dose escalation and high starting dose were
associated with $1498 and $688 higher total costs, respectively (both P  0.0001). 
With lower starting dose and dose escalation risk, escitalopram patients incurred $198 
lower regression-adjusted total costs (P  0.0007) than venlafaxine XR patients. 
CONCLUSIONS: Dose escalation and high initial dose are associated with signiﬁ -
cantly higher total costs for adult MDD patients. Compared to venlafaxine XR 
patients, escitalopram patients are less likely to dose escalate or start on high-dose
treatment, and incur lower total costs.
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OBJECTIVES: Lisdexamfetamine dimesylate (LDX), a therapeutically inactive mole-
cule, which after ingestion, is converted to l-lysine, and therapeutically active d-
amphetamine, is the ﬁ rst recently approved long-acting (LA) prodrug stimulant
indicated for the treatment of attention-deﬁ cit hyperactivity disorder (ADHD) in 
children and adults. This study examined adult patients in a US commercial health 
